Crispr Therapeutics

Yahoo Finance • 7 days ago

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

An updated edition of the Jan. 6, 2026, article. Genomics is the comprehensive study of genomes—the complete set of deoxyribonucleic acid (DNA) within an organism. Rapid scientific progress in this field has intensified interest among pha... Full story

Yahoo Finance • 7 days ago

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics(NASDAQ: CRSP), is the real buy for long-term investors. Shares of Vertex, a biotech based in Boston, popped last week after it re... Full story

Yahoo Finance • 13 days ago

Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI

Evercore ISI raised the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $62 and keeps an Outperform rating on the shares. The updated target reflects strong momentum as Vertex Pharmaceuticals’ (VRTX) new guidance for Casgevy... Full story

Yahoo Finance • 18 days ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 19 days ago

Cathie Wood buys $43 million of megacap tech stock

It’s been a rocky start to the year for Cathie Wood, the head of Ark Investment Management. As of Feb. 6, Wood’s flagship Ark Innovation ETF (ARKK) was down 9.58% year to date, while the S&P 500 gained 1.27%, as pressure mounted on growth... Full story

Yahoo Finance • 20 days ago

Insider trades: Merck, Intel, Micron among notable names

[Insider trading is shown on the business photo using the text] Andrii Dodonov A weekly overview of insider trading, highlighting significant purchases and sales by investors, directors, and executives. The transactions occurred between F... Full story

Yahoo Finance • 22 days ago

Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an Outperform rating on CRISPR Therapeutics while reducing the price target from $86 to $80. The firm highlighted that mu... Full story

Yahoo Finance • 25 days ago

C4 Therapeutics, Inc. (CCCC): A Bull Case Theory

We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.'s share was trading at $1.9600 as of January 29th. Copyright: dolg... Full story

Yahoo Finance • 2 months ago

Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story

Yahoo Finance • 2 months ago

TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock

This article first appeared on GuruFocus. Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (NASDAQ:TSLA) and Rocket Lab (NASDAQ:RKLB). Selling activity focused o... Full story

Yahoo Finance • 2 months ago

Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in... Full story

Yahoo Finance • 2 months ago

Cathie Wood Bets Big On Self-Driving and Gene-Editing Stocks Ahead of 2026

This article first appeared on GuruFocus. Cathie Wood's ARK Invest made additional portfolio adjustments, continuing moves seen in prior sessions. The firm increased holdings in WeRide Inc. (NASDAQ:WRD), a self-driving technology develop... Full story

Yahoo Finance • 2 months ago

Is CRISPR Therapeutics Stock Yesterday's News?

Key Points CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. 10 stocks we like better than CRISPR Therapeutics › CRIS... Full story

Yahoo Finance • 2 months ago

How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors

Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly... Full story

Yahoo Finance • 2 months ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

CRISPR Therapeutics AG -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell do... Full story

Yahoo Finance • 2 months ago

2 Growth Stocks to Invest $1,000 in Right Now

Key Points A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion. Such holdings come with risks, but they also... Full story

Yahoo Finance • 2 months ago

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the ne... Full story

Yahoo Finance • 2 months ago

12 Days of Investing: My Top 12 Stocks to Buy Before 2026

Key Points There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time. These 10 stocks could mint the next wave of millionaires › Soon, it will be countdown time, notin... Full story

Yahoo Finance • 3 months ago

uniQure N.V. (QURE): A Bear Case Theory

We came across a bearish thesis on uniQure N.V. on augur’s substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.'s share was trading at $27.51 as of November 28th. QURE’s forward P/E was 27.93 according to Ya... Full story

Yahoo Finance • 3 months ago

Cathie Wood's Ark Invest weekly recap: Boosts AI and Crypto Bets, Trims Palantir, GitLab, and AMD

[Investment. Businessman using laptop and analyzing data with investment growth on stock markets, startups, real estate, technology, and financial trends on global network.] Harsa Maduranga/iStock via Getty Images Cathie Wood’s ARK Invest... Full story